Design of a modular immunotoxin connected by polyionic adapter peptides

Journal of Molecular Biology

Volumn 327, Issue 2, 2003, Pages 445-452

  Kleinschmidt, Martin ^a   Rudolph, Rainer ^a   Lilie, Hauke ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Disulfide bond; Exotoxin; FACS; Fv fragment; Polyionic peptides

Indexed keywords

HYBRID PROTEIN; IMMUNOTOXIN; PEPTIDE;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; COVALENT BOND; GENETIC ENGINEERING; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS;

PSEUDOMONAS;

EID: 0037459221     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(03)00141-4     Document Type: Article

References (41)

1. Pastan I., Lovelace E.T., Gallo M.G., Rutherford A.V., Magnani J.L., Willingham M.C. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res. 51:1991;3781-3787.
2. Carter P. Improving the efficacy of antibody-based cancer therapies. Nature Rev. Cancer. 1:2001;118-129.
3. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:1999;2639-2648.
4. McLaughlin P., White C.A., Grillo-Lopez A.J., Maloney D.G. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology. 12:1998;1763-1769.
5. Kondo T., FitzGerald D., Chaudhary V.K., Adhya S., Pastan I. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J. Biol. Chem. 263:1988;9470-9475.
6. Pai L.H., Batra J.K., FitzGerald D.J., Willingham M.C., Pastan I. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys. Cancer Res. 52:1992;3189-3193.
7. Chaudhary V.K., Queen C., Junghans R.P., Waldmann T.A., FitzGerald D.J., Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 339:1989;394-397.
8. Kreitman R.J. Immunotoxins in cancer therapy. Curr. Opin. Immunol. 11:1999;570-578.
9. Brinkmann U., Keppler-Hafkemeyer A., Hafkemeyer P. Recombinant immunotoxins for cancer therapy. Expert Opin. Biol. Ther. 1:2001;693-702.
10. Reiter Y., Pai L.H., Brinkmann U., Wang Q.C., Pastan I. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res. 54:1994;2714-2718.
11. Kuan C.T., Pai L.H., Pastan I. Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin. Cancer Res. 1:1995;1589-1594.
12. Rybak S.M., Hoogenboom H.R., Meade H.M., Raus J.C., Schwartz D., Youle R.J. Humanization of immunotoxins. Proc. Natl Acad. Sci. USA. 89:1992;3165-3169.
13. Richter S., Stubenrauch K., Lilie H., Rudolph R. Artificial conjugation of proteins using polyionic fusion peptides. Protein Eng. 14:2001;775-783.
14. Stubenrauch K., Gleiter S., Brinkmann U., Rudolph R., Lilie H. Tumor cell specific targeting and gene transfer by recombinant polyoma virus like particle/antibody conjugates. Biochem. J. 356:2001;867-873.
15. Hwang J., Fitzgerald D.J., Adhya S., Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. Coli. Cell. 48:1987;129-136.
16. Beattie B.K., Merrill A.R. In vitro enzyme activation and folded stability of Pseudomonas aeruginosa exotoxin A and its C-terminal peptide. Biochemistry. 35:1996;9042-9051.
17. Beattie B.K., Merrill A.R. A fluorescence investigation of the active site of Pseudomonas aeruginosa exotoxin A. J. Biol. Chem. 274:1999;15646-15654.
18. Press O.W., Eary J.F., Appelbaum F.R., Martin P.J., Nelp W.B., Glenn S., et al. Phase II trial of 131 I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 346:1995;336-340.
19. Kaminski M.S., Zasadny K.R., Francis I.R., Fenner M.C., Ross C.W., Milik A.W., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14:1996;1974-1981.
20. Farah R.A., Clinchy B., Herrera L., Vitetta E.S. The development of monoclonal antibodies for the therapy of cancer. Crit. Rev. Eukaryot. Gene Expr. 8:1998;321-356.
21. van Beusechem V.W., Grill J., Mastenbroek D.C., Wickham T.J., Roelvink P.W., Haisma H.J., et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J. Virol. 76:2002;2753-2762.
22. Kuroki M., Arakawa F., Khare P.D., Kuroki M., Liao S., Matsumoto H., et al. Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA. Anticancer Res. 20:2001;4067-4071.
23. Gleiter S., Lilie H. Cell-type specific targeting and gene expression using a variant of polyoma VP1 virus-like particles. Biol. Chem. 384:2003;247-255.
24. May T., Gleiter S., Lilie H. Assessment of cell type specific gene transfer of polyoma virus like particles presenting a tumor specific antibody Fv fragment. J. Virol. Methods. 105:2002;147-155.
25. Park J.W., Hong K., Kirpotin D.B., Papahadjopoulos D., Benz C.C. Immunoliposomes for cancer treatment. Advan. Pharmacol. 40:1997;399-435.
26. Tsutsumi Y., Onda M., Nagata S., Lee B., Kreitman R.J., Pastan I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl Acad. Sci. USA. 97:2000;8548-8553.
27. Karpovsky B., Titus J.A., Stephany D.A., Segal D.M. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J. Expt. Med. 160:1984;1686-1701.
28. Muller K.M., Arndt K.M., Strittmatter W., Plückthun A. The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Letters. 422:1998;259-264.
29. Dübel S. Reconstitution of human RNase A from separate fragments fused to two different single chain antibody fragments: on the way to binary immunotoxins. Tumor Targeting. 4:1999;73-81.
30. Carr D.W., Stofko-Hahn R.E., Fraser J.D., Bishop S.M., Acott T.S., Brennan R.D., Scott J.D. Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J. Biol. Chem. 266:1991;14188-14192.
31. Pack P., Plückthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli. Biochemistry. 31:1992;1579-1584.
32. Taylor N., Flemington E., Kolman J.L., Baumann R.P., Speck S.H., Miller G. ZEBRA and a Fos-GCN4 chimeric protein differ in their DNA-binding specificities for sites in the Epstein-Barr virus BZLF1 promoter. J. Virol. 65:1991;4033-4041.
33. Granger-Schnarr M., Benusiglio E., Schnarr M., Sassone-Corsi P. Transformation and transactivation suppressor activity of the c-Jun leucine zipper fused to a bacterial repressor. Proc. Natl Acad. Sci. USA. 89:1992;4236-4239.
34. Chang H.C., Bao Z., Yao Y., Tse A.G., Goyarts E.C., Madsen M., et al. A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments. Proc. Natl Acad. Sci. USA. 91:1994;11408-11412.
35. Wu Z., Johnson K.W., Goldstein B., Choi Y., Eaton S.F., Laue T.M., Ciardelli T.L. Solution assembly of a soluble, heteromeric, high affinity interleukin-2 receptor complex. J. Biol. Chem. 270:1995;16039-16044.
36. Suzuki M., Saxena S.K., Boix E., Prill R.J., Vasandani V.M., Ladner J.E., et al. Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction. Nature Biotechnol. 17:1999;265-270.
37. Reiter Y., Brinkmann U., Webber K.O., Jung S.H., Lee B., Pastan I. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng. 5:1994;697-704.
38. Brinkmann U., Reiter Y., Jung S.H., Lee B., Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc. Natl Acad. Sci. USA. 90:1993;7538-7542.
39. Jung S.H., Pastan I., Lee B. Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins: Struct. Funct. Genet. 19:1994;35-47.
40. Rudolph R., Bohm G., Lilie H., Jaenicke R. Protein folding. Creighton T.E. Protein Function, a Practical Approach. 1997;57-99 IRL Press, Oxford.
41. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res. 47:1987;943-946.